Sean is joined by Dr. George Simon, Executive Director of Moffitt Cancer Center-AdventHealth joint Clinical Research Unit, to identify key crossroads in the treatment landscape for metastatic cancer patients. If the distinctions among systemic, local, and immunotherapies are a bit baffling to you they won't be for long. Dr. Simon details these and other approaches such as checkpoint inhibitors, available in the just the last five years or so. The pace of change is exhilarating for physicians and patients. Though there is still much to learn, there is also much to celebrate.
Speakers:
George Simon, M.D. - Executive Medical Director and Department Chair, Moffitt Cancer Center-AdventHealth joint Clinical Research Unit
Sean Shirvani, M.D. - Chief Medical Officer, RefleXion
For more information, please visit https://reflexion.com
Sean is joined by Dr. George Simon, Executive Director of Moffitt Cancer Center-AdventHealth joint Clinical Research Unit, to identify key crossroads in the treatment landscape for metastatic cancer patients. If the distinctions among systemic, local, and immunotherapies are a bit baffling to you they won't be for long. Dr. Simon details these and other approaches such as checkpoint inhibitors, available in the just the last five years or so. The pace of change is exhilarating for physicians and patients. Though there is still much to learn, there is also much to celebrate.
Speakers:
George Simon, M.D. - Executive Medical Director and Department Chair, Moffitt Cancer Center-AdventHealth joint Clinical Research Unit
Sean Shirvani, M.D. - Chief Medical Officer, RefleXion
For more information, please visit https://reflexion.com